The primary focus of retatrutide's clinical development is obesity and overweight , particularly in adults with weight-related health complications
However, researchers who plan on dosing the peptide for longer periods may consider lower doses, such as 10g/kg, because currently the peptide has not been studied clinically for more than 7 days
These might include an ultrasound to check for blood flow problems in your legs, as poor circulation can sometimes lead to cramps
However, its important to be aware of potential side effects, which may include nausea, vomiting, diarrhea, and injection site reactions
Pal S, Radavelli-Bagatini S